Results 141 to 150 of about 13,550 (188)

High-level cefiderocol and ceftazidime/avibactam resistance in KPC-producing Klebsiella pneumoniae associated with mutations in KPC and the sensor histidine kinase EnvZ. [PDF]

J Antimicrob Chemother
Findlay J, Bianco G, Boattini M, Nordmann P.   +3 more
europepmc   +1 more source

Emergence of Tigecycline-Nonsusceptible Carbapenem-Resistant <i>Klebsiella pneumoniae</i> with Metallo-β-Lactamase and Transferable Ceftazidime-Avibactam Resistance in China. [PDF]

Pathogens
Ni Y, Peng J, Xu Y, Zhu L, Wang X, Jin H, Qian H.   +6 more
europepmc   +1 more source

<i>In vivo</i> evolution of ceftazidime-avibactam resistance in <i>bla</i> _OXA-244-positive <i>E. coli</i> potentially linked to PBP3 insertion and mutations in <i>acrB</i> and PBP2. [PDF]

JAC Antimicrob Resist
Kocer K, Boutin S, Hansen G, Nurjadi D, Weidner NM.   +4 more
europepmc   +1 more source

A large-scale surveillance revealed that KPC variants mediated ceftazidime-avibactam resistance in clinically isolated Klebsiella pneumoniae. [PDF]

Microbiol Spectr
Qiao S, Xin S, Zhu Y, Zhao F, Wu H, Zhang J, Yao B, Yu Y, Fu Y, Jiang Y, Xie X, Zhang J.   +11 more
europepmc   +1 more source

Novel plasmid-mediated CMY variant (CMY-192) conferring ceftazidime-avibactam resistance in multidrug-resistant <i>Escherichia coli</i>. [PDF]

Antimicrob Agents Chemother
Xu T, Wu W, Huang L, Liu B, Zhang Q, Song J, Liu J, Li B, Li Z, Zhou K.   +9 more
europepmc   +1 more source

In vivo evolution to hypermucoviscosity and ceftazidime/avibactam resistance in a liver abscess caused by Klebsiella pneumoniae sequence type 512. [PDF]

mSphere
Capitani V, Arcari G, Ambrosi C, Scribano D, Ceparano M, Polani R, De Francesco A, Raponi G, Ceccarelli G, Villari P, Palamara AT, Marzuillo C, Carattoli A.   +12 more
europepmc   +1 more source

First report of KPC variants conferring ceftazidime-avibactam resistance in Colombia: introducing KPC-197. [PDF]

Microbiol Spectr
De la Cadena E, Mojica MF, Rojas LJ, Castro BE, García-Betancur JC, Marshall SH, Restrepo N, Castro-Caro NP, Fonseca-Carrillo M, Pallares C, Bonomo RA, Villegas MV.   +11 more
europepmc   +1 more source

Mechanisms leading to <i>in vivo</i> ceftazidime/avibactam resistance development during treatment of GES-5-producing <i>Pseudomonas aeruginosa</i> infections. [PDF]

Antimicrob Agents Chemother
Herrera C, Gomis-Font MA, López-Causapé C, Díez-Aguilar M, Fraile-Ribot PA, Cardeñoso LM, Oliver A.   +6 more
europepmc   +1 more source

Evolution of ceftazidime-avibactam resistance driven by variation in <i>bla</i> _KPC-2 to <i>bla</i> _KPC-190 during treatment of ST11-K64 hypervirulent <i>Klebsiella pneumoniae</i>. [PDF]

Front Cell Infect Microbiol
Liu Z, Lei J, Zhang X, Yin J, Zhang Y, Lei K, Geng Y, Huang L, Han Q, He A.   +9 more
europepmc   +1 more source

Correction for Qiao et al., "A large-scale surveillance revealed that KPC variants mediated ceftazidime-avibactam resistance in clinically isolated <i>Klebsiella pneumoniae</i>". [PDF]

Microbiol Spectr
Qiao S, Xin S, Zhu Y, Zhao F, Wu H, Zhang J, Yao B, Yu Y, Fu Y, Jiang Y, Xie X, Zhang J.   +11 more
europepmc   +1 more source